High-throughput SARS-CoV-2 and host genome sequencing from single nasopharyngeal swabs - Gorzynski, J. E.; De Jong, H. N.; Amar, D.; Hughes, C.; Ioannidis, A.; Bierman, R.; Liu, D.; Tanigawa, Y.; Kistler, A. L.; Kamm, J.; Kim, J.; Cappello, L.; et al. (medRxiv, 2020)
During COVID19 and other viral pandemics, rapid generation of host and pathogen genomic data is critical to tracking infection and informing therapies. There is an urgent need for efficient approaches to this data generation at scale. We have developed a scalable, high throughput approach to generate high fidelity low pass whole genome and HLA sequencing, viral genomes, and representation of human transcriptome from single nasopharyngeal swabs of COVID19 patients.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://docs.google.com/document/d/1g5tRzVPf2wRIRnJLXy4vL1_vsQBBYlHrP52RdPlRvM4/edit?usp=sharing https://docs.google.com/document/d/13nSWleTHJeL4fZkUFdQk9hUHsDVIzhJw52y_Zj2MqFc/edit?usp=sharing https://docs.google.com/document/d/1yyre73aVnQgLyY1XCtb4LbC7X_2_VV-SELqnn4QG5zU/edit?usp=sharing Funding StatementTakeda Pharmaceuticals provided funding support for nucleic acid extraction and library preparation. One Lambda, Inc supplied HLA sequencing reagents and software. The Chan Zuckerberg Initiative and Biohub supported all viral genome sequencing and alignment. This work is supported in part by NIH Common Fund (U24OD026629 to EAA and MTW), Arnold O. Beckman independence fellowship (MJS) and American Heart Association (MJS, KS), the National Heart Lung and Blood Institute (K08HL143185 to VNP), The John Taylor Babbitt Foundation (VNP) and Sarnoff Cardiovascular Research Foundation (VNP).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The STANFORD HRPP (Human Research Protection Program) has received Certification from the Consortium for Applied Research Ethics (CARE~Q) on July 16, 2018. Stanford received reaccreditation from the Association for Accreditation of Human Research Protection Programs (AAHRPP) on March 18, 2019. Federalwide Assurance number: FWA00000934 Expires: 01/29/2025. Stanford University IRBs are in compliance with Good Clinical Practices (ICH/GCP) as consistent with US Food and Drug Administration Code of Federal Regulations (21 CFR 50 and 56) and DHHS Regulations (45 CFR Part 46). https://researchcompliance.stanford.edu/panels/hs/about/registrationsAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data referred to in this manuscript is intended for sharing after necessary regulatory approval. At this time, please contact the corresponding authors directly for information on the status of approvals in accordance with the Stanford School of Medicine IRB.